We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

99 hedge funds and large institutions have $493M invested in Syndax Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

2% more funds holding

Funds holding: 97 → 99 (+2)

2% more capital invested

Capital invested by funds: $484M → $493M (+$9.52M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less call options, than puts

Call options by funds: $1.12M | Put options by funds: $1.24M

1.63% less ownership

Funds ownership: 90.44% → 88.81% (-1.6%)

22% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 36

Holders
99
Holders Change
+2
Holders Change %
+2.06%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
16
Increased
28
Reduced
36
Closed
14
Calls
$1.12M
Puts
$1.24M
Net Calls
-$122K
Net Calls Change
-$10.5M

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$20.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.91M
3
State Street
State Street
Massachusetts
+$9.84M
4
APM
Avidity Partners Management
Texas
+$4.98M
5
SFM
Sphera Funds Management
Israel
+$4.42M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$7.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.5M
3
MAM
MPM Asset Management
Massachusetts
-$4.96M
4
BlackRock
BlackRock
New York
-$4.05M
5
DCM
DAFNA Capital Management
California
-$3.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$3.82M +$892K +58,500 +29%
Goldman Sachs
27
Goldman Sachs
New York
$3.72M -$2.83M -185,492 -42%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$3.68M +$2.27M +148,836 +148%
ACP
29
Acuta Capital Partners
California
$3.55M – – –
Two Sigma Investments
30
Two Sigma Investments
New York
$3.35M -$1.95M -128,122 -36%
PAI
31
Palo Alto Investors
California
$2.93M +$1.08M +70,700 +55%
N
32
Nuveen
North Carolina
$2.75M +$1.06M +69,338 +59%
Charles Schwab
33
Charles Schwab
California
$2.71M +$1.79M +117,149 +176%
Macquarie Group
34
Macquarie Group
Australia
$2.66M – – –
Assenagon Asset Management
35
Assenagon Asset Management
Luxembourg
$2.51M -$128K -8,400 -5%
Point72 Asset Management
36
Point72 Asset Management
Connecticut
$2.45M +$2.53M +166,037 New
Russell Investments Group
37
Russell Investments Group
United Kingdom
$1.84M +$319K +20,914 +20%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.53M +$274 +18 +0%
DCM
39
DAFNA Capital Management
California
$1.52M -$3.92M -257,287 -71%
Squarepoint
40
Squarepoint
New York
$967K +$689K +45,171 +222%
Invesco
41
Invesco
Georgia
$966K +$997K +65,438 New
Wells Fargo
42
Wells Fargo
California
$926K -$374K -24,510 -28%
CS
43
Credit Suisse
Switzerland
$908K +$147K +9,641 +19%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$899K +$19.8K +1,300 +2%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$853K +$268K +17,600 +44%
PAM
46
Panagora Asset Management
Massachusetts
$816K -$216K -14,186 -20%
AQR Capital Management
47
AQR Capital Management
Connecticut
$634K -$28.6K -1,873 -4%
Morgan Stanley
48
Morgan Stanley
New York
$633K -$1.63M -107,192 -71%
Ensign Peak Advisors
49
Ensign Peak Advisors
Utah
$604K +$351K +23,023 +128%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$600K +$869 +57 +0.1%
1
2
3 4 5

SNDX Hedge Fund Activity: Q3 2020 in Review

99 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2020, worth a combined $493M — up 2% from $484M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SNDX positions and 14 closed out — a net gain of 2 holders — while 28 added to existing stakes and 36 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $20.4M. The largest seller was Citadel Advisors, cutting an estimated $7.3M.

  • 99 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2020, up from 97 in Q2 2020.
  • Funds reported $493M of Syndax Pharmaceuticals stock for Q3 2020, up 2% quarter-over-quarter.
  • 16 funds opened new Syndax Pharmaceuticals positions in Q3 2020 and 14 closed out, a net change of +2 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2020 was Nantahala Capital Management, an estimated $20.4M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $7.3M sold.

Based on aggregated 13F filings for Q3 2020.